Barry E. Storer

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Clinical Statistics
Clinical Research
Member, Appointed: 1995
University of Washington
School of Public Health and Community Medicine
Biostatistics
Affiliate Professor, Appointed: 1996
Fred Hutchinson Cancer Research Center
Public Health Sciences
Member, Appointed: 1995
Professional Headshot of Barry E. Storer

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N., D5-360
P.O. Box 19024
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-6151
Fax: (206) 667-6358
bstorer@fhcrc.org

Degrees

Ph.D., University of Washington, Biostatistics, 1984.
M.A., University of Montana, Zoology, 1977.
B.A., University of New Hampshire, Zoology, 1973.

Research Interests

Biostatistical Methods And Applications In Clinical Trials And Epidemiology.

Although considerable attention has been paid to the design and analysis of Phase III clinical trials (randomized controlled trials of efficacy), relatively less effort has been directed to Phase II (uncontrolled trials of efficacy, often with surrogate endpoints) and especially Phase I (dose-finding trials evaluating toxicity) clinical trials. I have collaborated for many years with clinicians conducting Phase I clinical trials of anti-cancer agents, both traditional cytotoxic drugs and biological agents.

In typical designs for such studies, a starting dose level and a sequence of increasing dose levels thereafter are determined based on the results of toxicity trials in animals. Small cohorts of patients (3-6 per dose level) are entered beginning at the first dose level. Subsequent cohorts are entered either at the next higher dose level, or the trial is stopped, depending on the toxicity experience in the current cohort, according to a predetermined algorithm.

One of my research interests has been to evaluate the operating characteristics of designs of this type and to consider designs that differ from the standard. The operating characteristics of a design unfortunately depend to a large extent on the true dose-toxicity curve, which is unknown; however, Monte Carlo simulations conducted over a wide range of plausible dose-response settings can provide useful information regarding the performance of the design and enable a clinician to choose a particular design based on objective characteristics.

Here at the Fred Hutchinson Cancer Research Center, some Phase I trials in the stem cell transplant program can be designed to address dose-finding with respect to both toxicity and efficacy in the same patient population. For example, a drug used to prevent graft versus host disease (GVHD) may be more effective at a higher dose but also have greater toxicity, and the goal is to find a dose that achieves a desirable combination of efficacy and safety. The design of such trials is of interest to myself and other statisticians in the Clinical Research Division.

Other methodologic work has focused on the design of Phase II trials, as well as diagnostics for identifying unusually influential observations in regression analysis.

Memberships

American Statistical Association
Biometric Society
Society for Clinical Trials

Previous Positions

1992-1995, Associate Professor, University of Wisconsin, Statistics, Biostatistics
1990-1992, Associate Professor, University of Wisconsin, Statistics, Human Oncology
1984-1995, Member, University of Wisconsin, Comprehensive Cancer Center
1984-1990, Assistant Professor, University of Wisconsin, Statistics, Human Oncology
1981-1983, Research Associate, Fred Hutchinson Cancer Research Center, National Wilms Tumor Study
1979-1981, Research Associate, University of Washington, School of Public Health and Community Medicine, Biostatistics
-1984, Assistant Staff Scientist, Fred Hutchinson Cancer Research Center, Public Health Sciences

Recent Publications

2014
Bemer, MJ, Risler LJ, Phillips BR, Wang J, Storer BE, Sandmaier BM, Duan H, Raccor BS, Boeckh MJ, McCune JS.  2014.  Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity In Nonmyeloablative Hct.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
2013
Hansen, JA, Hanash SM, Tabellini L, Baik C, Lawler RL, Grogan BM, Storer BE, Chin A, Johnson M, Wong C-H et al..  2013.  A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract